Patent · US Active

Forms of rifaximin and uses thereof

US8513275B2 · kind B2 · utility

7Cited by

1References

6Claims

0Family size

Assignee

Salix Pharmaceuticals, Inc. · US

Inventors

Yiduo Wu · New Brunswick, US
Stephan D. Parent · West Lafayette, US
Nathan Carl Schultheiss · Kingwood, US
Melanie Janelle Bevill · West Lafayette, US
Petinka Vlahova · West Lafayette, US
Travis L. Houston · Lafayette, US

Key dates

Filing date	Jun 3, 2011
Grant date	Aug 20, 2013
Priority date	—
Expiry date	Jun 3, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D491/048
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to new rifaximin forms kappa, theta, rifaximin:piperazine cocrystal 1 and rifaximin:piperazine cocrystal 2, methods of making same and to their use in medicinal preparations and therapeutic methods.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.